Stoke Therapeutics, Inc. Other Current Liabilities
Stoke Therapeutics, Inc. (STOK) had Other Current Liabilities of $1.62 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-03
- 2026-06-30: Other Liabilities, Current $1.62M.
- 2026-03-31: Other Liabilities, Current $1.50M.
- 2025-12-31: Other Liabilities, Current $1.06M.
- 2025-09-30: Other Liabilities, Current $795.00K.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.62M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.06M 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $795.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.75M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $2.07M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $753.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $597.00K 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $1.04M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $980.00K 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $857.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $472.00K 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $703.00K 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $506.00K 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $509.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $426.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $750.00K 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $523.00K 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $540.00K 10-K · filed 2023-03-06 | |
| 2021-09-30 | $328.00K 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $586.00K 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $1.17M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $459.00K 10-K · filed 2022-03-10 | $1.44M 10-K · filed 2021-03-09 |
| 2020-09-30 | $255.00K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $495.00K 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $54.00K 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $54.00K 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |